RenovaCare
RenovaCare is a publicly traded clinical-stage biotechnology company developing autologous stem cell therapies for skin regeneration using its CellMist™ System and patented SkinGun™ spray device, targeting burns, chronic wounds, and skin defects.
- Company typePrivate
- Founded1983
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What RenovaCare does
RenovaCare, Inc. is a clinical-stage biotechnology company developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs, with its initial focus on the skin, the body's largest organ. Its flagship platform, the CellMist™ System, harvests a patient's stem cells from a small skin sample of approximately one square inch, suspends them in a water-based CellMist™ Solution, and applies the suspension onto wounds using the patented SkinGun™ deposition device. The SkinGun™ employs a gentle positive-pressure air stream rather than a high-pressure pump, which the company claims better preserves fragile cells during application. The complete procedure can reportedly take as little as 90 minutes, with potential for patient discharge within days rather than weeks compared with in-vitro cultured epithelial grafts.
The company targets an estimated 143 million patients worldwide suffering burns, chronic and acute wounds, acne scarring, and skin defects including vitiligo, addressing what it characterizes as a $45 billion US market opportunity. RenovaCare is publicly traded on the OTCQB under ticker RCAR, headquartered in New York, and operates with a lean team of 1-10 employees. Its products are in investigational clinical use for second-degree burn patients in the United States but are not yet approved for sale. The company is also developing adjacent medical-grade liquid spray devices for wound care and irrigation fluids. Future revenue is expected to come from commercial sales of the CellMist™ System and SkinGun™ device to hospitals and clinical settings, but no commercial go-to-market has commenced, and no customers, distribution partners, or pricing have been disclosed.
RenovaCare firmographics
Firmographics- Name
- RenovaCare
- Legal name
- RenovaCare, Inc.
- Website
- https://renovacareinc.com
- Company type
- Private
- Founded year
- 1983
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RenovaCare is a publicly traded clinical-stage biotechnology company developing autologous stem cell therapies for skin regeneration using its CellMist™ System and patented SkinGun™ spray device, targeting burns, chronic wounds, and skin defects.
- Ownership category
- akta.pro rank
RenovaCare industry classification
Industry- Product category
- Regenerative Medicine Biotechnology
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
- akta.pro secondary industries
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound & Ostomy Skin Care (Barrier Films/Creams, Adhesive Removers, Cleansers) (HLAHALAK), Ambulatory Wound Care & Hyperbaric Oxygen Therapy Centers (HLAFABAG)
Keywords
Where RenovaCare is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
RenovaCare business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Future Product Sales: RenovaCare is a clinical stage biotechnology company with products under development and not yet approved for sale in the United States. Future revenue is expected to come from commercial sales of the CellMist™ System and SkinGun™ device for burn and wound treatment.
Go-to-market motion1 record
Marketing channels1 record
RenovaCare product offering
Product offeringCore offering
RenovaCare is developing the CellMist™ System, an autologous stem cell therapy platform that harvests a patient's own stem cells from approximately 1 square inch of skin and suspends them in a water-based CellMist™ Solution. The suspension is then gently sprayed onto wounds using the patented SkinGun™ device, which uses a positive-pressure air stream designed to protect fragile cells from damage. The product targets burns, chronic and acute wounds, acne scarring, and skin defects such as vitiligo, and is currently in investigational clinical use in the United States for second-degree burn patients.
Product overview
RenovaCare is developing a unified stem cell therapy platform centered on the CellMist™ System, which comprises the patented SkinGun™ spray device and the CellMist™ Solution (a water-based suspension of the patient's own harvested stem cells). The system is designed to spray the stem cell suspension onto burns and wounds to promote rapid, natural skin regeneration. The company is also expanding its portfolio with medical-grade liquid spray devices for wound care and irrigation fluids. All products are under development and not yet approved for sale in the United States.
Differentiator
Problem solved
Functional benefit
Products and services
- CellMist™ System Flagship integrated autologous stem cell therapy platform that harvests a patient's stem cells from approximately 1 square inch of skin, suspends them in the CellMist™ Solution, and sprays the suspension onto wounds using the SkinGun™ device to promote natural skin regeneration at the cellular level. Targeted at hospitals and clinical settings treating burns, chronic/acute wounds, acne scarring, and skin defects.
- SkinGun™ Patented spray deposition device that delivers the CellMist™ Solution onto wounds using a gentle positive-pressure air stream, designed to protect fragile autologous stem cells from the shear damage caused by high-pressure pump spray devices.
- CellMist™ Solution Water-based suspension of a patient's own (autologous) stem cells harvested from approximately 1 square inch of skin, designed to be sprayed onto wounds to promote natural skin regeneration at the cellular level.
- Medical-grade Liquid Spray Devices Medical-grade spray devices for wound care and irrigation fluids, expanding RenovaCare's portfolio beyond its core autologous stem cell therapy system.
Quantifiable outcome
- Procedure can take as little as 90 minutes from start to finish
- +2 more outcomes
Companies that use RenovaCare
Customer profileSegments1 record
Ideal customer profiles1 record
RenovaCare technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
RenovaCare partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights4 records
RenovaCare competitors and assessment
Company assessmentDirect peers
- Organogenesis: Commercial-stage regenerative medicine company with approved skin substitutes (e.g., Apligraf) used in wound care and burns — the most directly comparable commercial competitor to RenovaCare's target market.
- Vericel: Develops autologous cell therapies including Epicel for severe burns, making it a closely matched direct competitor in autologous skin regeneration with an already-approved burn product.
- AVITA Medical: Regenerative medicine company with an FDA-approved autologous skin cell spray device (RECELL) for burns, representing the most direct functional competitor to RenovaCare's SkinGun/CellMist concept.
- MiMedx: Commercial-stage company developing placental tissue-based regenerative products for wound care and surgical recovery, competing in the same skin/wound regeneration category.
Broad incumbents
- Integra LifeSciences: Large medical device company with a portfolio of regenerative skin and wound care products (e.g., Integra Dermal Regeneration Template) serving burns and chronic wounds — broad incumbent with overlapping indications.
- Smith+Nephew: Global medical device incumbent with a substantial advanced wound management portfolio, competing with RenovaCare's chronic and acute wound targets.
- Convatec: Global wound care company with advanced dressings and skin substitute products, addressing the same chronic/acute wound segment as RenovaCare's pipeline.
- Coloplast (Wound Care): Major wound care incumbent with advanced dressings and skin care solutions for chronic wounds, competing for the same hospital and clinical channel RenovaCare plans to enter.
Emerging players
- PolarityTE: Clinical-stage regenerative medicine company developing autologous skin and soft tissue products (SkinTE), closely aligned in approach and stage with RenovaCare.
- TissueTech: Regenerative medicine company commercializing placental membrane-based products for wound care and ophthalmology, an emerging player in the broader regenerative skin/wound space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
RenovaCare social profiles
Digital presenceRenovaCare financial estimates
Financial estimateRevenue estimate
Valuation estimate
RenovaCare leadership team
Management profileNumber of profiles
Profiles4 records
RenovaCare funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RenovaCare M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RenovaCare
What does RenovaCare do?
RenovaCare is developing the CellMist™ System, an autologous stem cell therapy platform that harvests a patient's own stem cells from approximately 1 square inch of skin and suspends them in a water-based CellMist™ Solution. The suspension is then gently sprayed onto wounds using the patented SkinGun™ device, which uses a positive-pressure air stream designed to protect fragile cells from damage. The product targets burns, chronic and acute wounds, acne scarring, and skin defects such as vitiligo, and is currently in investigational clinical use in the United States for second-degree burn patients.
Is RenovaCare a public or private company?
RenovaCare is a private company. It is classified as public and is currently operating.
When was RenovaCare founded?
RenovaCare was founded in 1983. It employs 1 to 10 people.
Where is RenovaCare based?
RenovaCare is headquartered in New York, United States, in the North America region.
How does RenovaCare make money?
One revenue line is on record: future Product Sales.
Who are RenovaCare's main competitors?
Direct peers on record are Organogenesis, Vericel, AVITA Medical and MiMedx. Broad incumbents are Integra LifeSciences, Smith+Nephew, Convatec and Coloplast (Wound Care). Emerging players are PolarityTE and TissueTech.
Does RenovaCare have an API?
No public API is recorded for RenovaCare.
What industry is RenovaCare in?
RenovaCare's product category is Regenerative Medicine Biotechnology. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 3391 and its SIC code is 3841.